Erratum: Suppression of NF-κB activity via nanoparticlebased siRNA delivery alters early cartilage responses to injury (Proceedings of the National Academy of Sciences of the United States of America (2016) 113 (E6199-E6208) DOI: 10.1073/pnas.1608245113);Suppression of NF-κB activity via nanoparticle-based siRNA delivery alters early cartilage responses to injury

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 41, 2016, Pages E6199-E6208

  Yan, Huimin ^a   Duan, Xin ^a   Pan, Hua ^a   Holguin, Nilsson ^a   Rai, Muhammad Farooq ^a   Akk, Antonina ^a   Springer, Luke E ^a   Wickline, Samuel A ^a   Sandell, Linda J ^a   Pham, Christine T N ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autophagy; Nanomedicine; NF B; Posttraumatic osteoarthritis; SiRNA

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ALBUMIN; BETA CATENIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MICROTUBULE ASSOCIATED PROTEIN; MICROTUBULE ASSOCIATED PROTEIN LIGHT CHAIN 3; NANOPARTICLE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PEPTIDE; PROTEIN P100; PROTEIN S6; PROTEOGLYCAN; SMALL INTERFERING RNA; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ATOMIC FORCE MICROSCOPY; AUTOPHAGY; CARTILAGE CELL; CARTILAGE EXPLANT; CARTILAGE INJURY; CELL DEATH; CELL SURVIVAL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; HISTOPATHOLOGY; HOMEOSTASIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KNEE INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SYNOVITIS; SYNOVIUM; TRANSMISSION ELECTRON MICROSCOPY; TUNEL ASSAY; UPREGULATION;

EID: 84991517844     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1703622114     Document Type: Erratum

References (57)

1. Hootman JM, Helmick CG (2006) Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum 54(1):226-229.
2. Brown TD, Johnston RC, Saltzman CL, Marsh JL, Buckwalter JA (2006) Posttraumatic osteoarthritis: A first estimate of incidence, prevalence, and burden of disease. J Orthop Trauma 20(10):739-744.
3. Chalmers PN, et al. (2014) Does ACL reconstruction alter natural history?: A systematic literature review of long-term outcomes. J Bone Joint Surg Am 96(4):292-300.
4. Lieberthal J, Sambamurthy N, Scanzello CR (2015) Inflammation in joint injury and post-traumatic osteoarthritis. Osteoarthritis Cartilage 23(11):1825-1834.
5. Wu P, et al. (2014) Early response of mouse joint tissue to noninvasive knee injury suggests treatment targets. Arthritis Rheumatol 66(5):1256-1265.
6. Marcu KB, Otero M, Olivotto E, Borzi RM, Goldring MB (2010) NF-kappaB signaling: Multiple angles to target OA. Curr Drug Targets 11(5):599-613.
7. Setton L (2008) Polymer therapeutics: Reservoir drugs. Nat Mater 7(3):172-174.
8. Hou KK, Pan H, Lanza GM, Wickline SA (2013) Melittin derived peptides for nanoparticle based siRNA transfection. Biomaterials 34(12):3110-3119.
9. Hou KK, Pan H, Ratner L, Schlesinger PH, Wickline SA (2013) Mechanisms of nanoparticle-mediated siRNA transfection by melittin-derived peptides. ACS Nano 7(10):8605-8615.
10. Zhou HF, et al. (2014) Peptide-siRNA nanocomplexes targeting NF-κB subunit p65 suppress nascent experimental arthritis. J Clin Invest 124(10):4363-4374.
11. Pan H, et al. (2010) Lipid membrane editing with peptide cargo linkers in cells and synthetic nanostructures. FASEB J 24(8):2928-2937.
12. Pan H, et al. (2011) Post-formulation peptide drug loading of nanostructures for metered control of NF-kB signaling. Biomaterials 32(1):231-238.
13. Pan H, et al. (2013) Programmable nanoparticle functionalization for in vivo targeting. FASEB J 27(1):255-264.
14. Caramés B, Taniguchi N, Otsuki S, Blanco FJ, Lotz M (2010) Autophagy is a protective mechanism in normal cartilage, and its aging-related loss is linked with cell death and osteoarthritis. Arthritis Rheum 62(3):791-801.
15. Sasaki H, et al. (2012) Autophagy modulates osteoarthritis-related gene expression in human chondrocytes. Arthritis Rheum 64(6):1920-1928.
16. Trocoli A, Djavaheri-Mergny M (2011) The complex interplay between autophagy and NF-kB signaling pathways in cancer cells. Am J Cancer Res 1(5):629-649.
17. Baldwin AS (2012) Regulation of cell death and autophagy by IKK and NF-kB: Critical mechanisms in immune function and cancer. Immunol Rev 246(1):327-345.
18. Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149(2):274-293.
19. Meley D, et al. (2006) AMP-activated protein kinase and the regulation of autophagic proteolysis. J Biol Chem 281(46):34870-34879.
20. Inoki K, Kim J, Guan KL (2012) AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol 52:381-400.
21. Bohensky J, Leshinsky S, Srinivas V, Shapiro IM (2010) Chondrocyte autophagy is stimulated by HIF-1 dependent AMPK activation and mTOR suppression. Pediatr Nephrol 25(4):633-642.
22. Terkeltaub R, Yang B, Lotz M, Liu-Bryan R (2011) Chondrocyte AMP-activated protein kinase activity suppresses matrix degradation responses to proinflammatory cytokines interleukin-1p and tumor necrosis factor a. Arthritis Rheum 63(7):1928-1937.
23. Zhao J, Yue W, Zhu MJ, Sreejayan N, Du M (2010) AMP-activated protein kinase (AMPK) cross-talks with canonical Wnt signaling via phosphorylation of beta-catenin at Ser 552. Biochem Biophys Res Commun 395(1):146-151.
24. Takatani T, Minagawa M, Takatani R, Kinoshita K, Kohno Y (2011) AMP-activated protein kinase attenuates Wnt/p-catenin signaling in human osteoblastic Saos-2 cells. Mol Cell Endocrinol 339(1-2):114-119.
25. Zhao JX, Yue WF, Zhu MJ, Du M (2011) AMP-activated protein kinase regulates betacatenin transcription via histone deacetylase 5. J Biol Chem 286(18):16426-16434.
26. Corr M (2008) Wnt-beta-catenin signaling in the pathogenesis of osteoarthritis. Nat Clin Pract Rheumatol 4(10):550-556.
27. Naeye B, et al. (2013) In vivo disassembly of IV administered siRNA matrix nanoparticles at the renal filtration barrier. Biomaterials 34(9):2350-2358.
28. Kanasty RL, Whitehead KA, Vegas AJ, Anderson DG (2012) Action and reaction: The biological response to siRNA and its delivery vehicles. Mol Ther 20(3):513-524.
29. Roman-Blas JA, Jimenez SA (2006) NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 14(9):839-848.
30. DeStefano D (2011) Oligonucleotides decoy to NF-kappaB: Becoming a reality? Discov Med 12(63):97-105.
31. Chen LX, et al. (2008) Suppression of early experimental osteoarthritis by in vivo delivery of the adenoviral vector-mediated NF-kappaBp65-specific siRNA. Osteoarthritis Cartilage 16(2):174-184.
32. Wang D, Gao G (2014) State-of-the-art human gene therapy: Part I. Gene delivery technologies. Discov Med 18(97):67-77.
33. Chira S, et al. (2015) Progresses towards safe and efficient gene therapy vectors. Oncotarget 6(31):30675-30703.
34. Castanotto D, Rossi JJ (2009) The promises and pitfalls of RNA-interference-based therapeutics. Nature 457(7228):426-433.
35. Merkel OM, et al. (2011) Polymer-related off-target effects in non-viral siRNA delivery. Biomaterials 32(9):2388-2398.
36. Soman NR, et al. (2009) Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. J Clin Invest 119(9):2830-2842.
37. Soman NR, Lanza GM, Heuser JM, Schlesinger PH, Wickline SA (2008) Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides. Nano Lett 8(4):1131-1136.
38. Hou KK, Pan H, Schlesinger PH, Wickline SA (2015) A role for peptides in overcoming endosomal entrapment in siRNA delivery: A focus on melittin. Biotechnol Adv 33(6 Pt 1):931-940.
39. Hoesel B, Schmid JA (2013) The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer 12:86.
40. Noort AR, Tak PP, Tas SW (2015) Non-canonical NF-κB signaling in rheumatoid arthritis: Dr Jekyll and Mr Hyde? Arthritis Res Ther 17:15.
41. Beg AA, Baltimore D (1996) An essential role for NF-kappaB in preventing TNF-alphainduced cell death. Science 274(5288):782-784.
42. Wang CY, Mayo MW, Baldwin AS, Jr (1996) TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kappaB. Science 274(5288):784-787.
43. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM (1996) Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 274(5288):787-789.
44. Liu ZG, Hsu H, Goeddel DV, Karin M (1996) Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 87(3):565-576.
45. Kim SJ, Hwang SG, Shin DY, Kang SS, Chun JS (2002) p38 kinase regulates nitric oxideinduced apoptosis of articular chondrocytes by accumulating p53 via NFkappa B-dependent transcription and stabilization by serine 15 phosphorylation. J Biol Chem 277(36):33501-33508.
46. Kim SJ, Chun JS (2003) Protein kinase C alpha and zeta regulate nitric oxide-induced NF-kappa B activation that mediates cyclooxygenase-2 expression and apoptosis but not dedifferentiation in articular chondrocytes. Biochem Biophys Res Commun 303(1):206-211.
47. Zhang Y, et al. (2015) Cartilage-specific deletion of mTOR upregulates autophagy and protects mice from osteoarthritis. Ann Rheum Dis 74(7):1432-1440.
48. Caramés B, et al. (2012) Autophagy activation by rapamycin reduces severity of experimental osteoarthritis. Ann Rheum Dis 71(4):575-581.
49. Takayama K, et al. (2014) Local intra-articular injection of rapamycin delays articular cartilage degeneration in a murine model of osteoarthritis. Arthritis Res Ther 16(6):4-2.
50. Sag D, Carling D, Stout RD, Suttles J (2008) Adenosine 5'-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J Immunol 181(12):8633-8641.
51. Yang Z, Kahn BB, Shi H, Xue BZ (2010) Macrophage alpha1 AMP-activated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J Biol Chem 285(25):19051-19059.
52. Galic S, et al. (2011) Hematopoietic AMPK β1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity. J Clin Invest 121(12):4903-4915.
53. Nath N, et al. (2005) 5-Aminoimidazole-4-carboxamide ribonucleoside: A novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis. J Immunol 175(1):566-574.
54. Zhao X, et al. (2008) Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury. Am J Physiol Lung Cell Mol Physiol 295(3):L497-L504.
55. Bai A, et al. (2010) AMPK agonist downregulates innate and adaptive immune responses in TNBS-induced murine acute and relapsing colitis. Biochem Pharmacol 80(11):1708-1717.
56. Salminen A, Hyttinen JM, Kaarniranta K (2011) AMP-activated protein kinase inhibits NF-κB signaling and inflammation: Impact on healthspan and lifespan. J Mol Med (Berl) 89(7):667-676.
57. Shapiro IM, Layfield R, Lotz M, Settembre C, Whitehouse C (2014) Boning up on autophagy: The role of autophagy in skeletal biology. Autophagy 10(1):7-19.